These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
375 related articles for article (PubMed ID: 17687649)
1. Age interacts with the expression of steroid and HER-2 receptors in operable invasive breast cancer. Neven P; Van Calster B; Van den Bempt I; Van Huffel S; Van Belle V; Hendrickx W; Decock J; Wildiers H; Paridaens R; Amant F; Leunen K; Berteloot P; Timmerman D; Van Limbergen E; Weltens C; Van den Bogaert W; Smeets A; Vergote I; Christiaens MR; Drijkoningen M Breast Cancer Res Treat; 2008 Jul; 110(1):153-9. PubMed ID: 17687649 [TBL] [Abstract][Full Text] [Related]
2. Axillary lymph node status of operable breast cancers by combined steroid receptor and HER-2 status: triple positive tumours are more likely lymph node positive. Van Calster B; Vanden Bempt I; Drijkoningen M; Pochet N; Cheng J; Van Huffel S; Hendrickx W; Decock J; Huang HJ; Leunen K; Amant F; Berteloot P; Paridaens R; Wildiers H; Van Limbergen E; Weltens C; Timmerman D; Van Gorp T; Smeets A; Van den Bogaert W; Vergote I; Christiaens MR; Neven P Breast Cancer Res Treat; 2009 Jan; 113(1):181-7. PubMed ID: 18264760 [TBL] [Abstract][Full Text] [Related]
3. Estrogen receptor-positive, progesterone receptor-negative breast cancer: association with growth factor receptor expression and tamoxifen resistance. Arpino G; Weiss H; Lee AV; Schiff R; De Placido S; Osborne CK; Elledge RM J Natl Cancer Inst; 2005 Sep; 97(17):1254-61. PubMed ID: 16145046 [TBL] [Abstract][Full Text] [Related]
4. Association between HER-2/neu and the progesterone receptor in oestrogen-dependent breast cancer is age-related. Huang HJ; Neven P; Drijkoningen M; Paridaens R; Wildiers H; Van Limbergen E; Berteloot P; Amant F; Christiaens MR; Vergote I Breast Cancer Res Treat; 2005 May; 91(1):81-7. PubMed ID: 15868434 [TBL] [Abstract][Full Text] [Related]
5. Short-term outcome of primary operated early breast cancer by hormone and HER-2 receptors. Brouckaert O; Pintens S; Van Belle V; Van Huffel S; Camerlynck E; Amant F; Leunen K; Smeets A; Berteloot P; Van Limbergen E; Decock J; Hendrickx W; Weltens C; Van den Bogaert W; Vanden Bempt I; Drijkoningen M; Paridaens R; Wildiers H; Vergote I; Christiaens MR; Neven P Breast Cancer Res Treat; 2009 May; 115(2):349-58. PubMed ID: 18629635 [TBL] [Abstract][Full Text] [Related]
6. Prognostic implications of HER-2 status in steroid receptor-positive, lymph node-negative breast carcinoma. Peiró G; Adrover E; Aranda FI; Peiró FM; Niveiro M; Sánchez-Payá J Am J Clin Pathol; 2007 May; 127(5):780-6. PubMed ID: 17439837 [TBL] [Abstract][Full Text] [Related]
7. Surgical specimen can be replaced by core samples in assessment of ER, PR and HER-2 for invasive breast cancer. Sutela A; Vanninen R; Sudah M; Berg M; Kiviniemi V; Rummukainen J; Kataja V; Kärjä V Acta Oncol; 2008; 47(1):38-46. PubMed ID: 17851859 [TBL] [Abstract][Full Text] [Related]
8. Body mass index and HER-2 overexpression in breast cancer patients over 50 years of age. Van Mieghem T; Leunen K; Pochet N; De Moor B; De Smet F; Amant F; Berteloot P; Timmerman D; Vanden Bempt I; Drijkoningen R; Wildiers H; Paridaens R; Smeets A; Hendrickx W; Van Limbergen E; Christiaens MR; Vergote I; Neven P Breast Cancer Res Treat; 2007 Nov; 106(1):127-33. PubMed ID: 17211534 [TBL] [Abstract][Full Text] [Related]
9. Triple negative breast cancer: a study from the point of view of basal CK5/6 and HER-1. Pintens S; Neven P; Drijkoningen M; Van Belle V; Moerman P; Christiaens MR; Smeets A; Wildiers H; Vanden Bempt I J Clin Pathol; 2009 Jul; 62(7):624-8. PubMed ID: 19561231 [TBL] [Abstract][Full Text] [Related]
10. Poor hormone receptor expression in East African breast cancer: evidence of a biologically different disease? Bird PA; Hill AG; Houssami N Ann Surg Oncol; 2008 Jul; 15(7):1983-8. PubMed ID: 18408976 [TBL] [Abstract][Full Text] [Related]
11. Human epidermal growth factor receptor 2 status correlates with lymph node involvement in patients with estrogen receptor (ER) negative, but with grade in those with ER-positive early-stage breast cancer suitable for cytotoxic chemotherapy. Bartlett JM; Ellis IO; Dowsett M; Mallon EA; Cameron DA; Johnston S; Hall E; A'Hern R; Peckitt C; Bliss JM; Johnson L; Barrett-Lee P; Ellis P J Clin Oncol; 2007 Oct; 25(28):4423-30. PubMed ID: 17906205 [TBL] [Abstract][Full Text] [Related]
12. Scoring index for prediction of HER-2 status in the invasive breast carcinoma. Kajo K; Zubor P; Barthova M; Plank L Exp Oncol; 2007 Dec; 29(4):281-6. PubMed ID: 18199984 [TBL] [Abstract][Full Text] [Related]
13. Histopathologic characteristics predicting HER-2/neu amplification in breast cancer. Prati R; Apple SK; He J; Gornbein JA; Chang HR Breast J; 2005; 11(6):433-9. PubMed ID: 16297088 [TBL] [Abstract][Full Text] [Related]
14. Prognostic utility of fluorescence in situ hybridization for determining HER2 gene amplification in breast cancer. Kammori M; Kurabayashi R; Kashio M; Sakamoto A; Yoshimoto M; Amano S; Kaminishi M; Yamada T; Takubo K Oncol Rep; 2008 Mar; 19(3):651-6. PubMed ID: 18288397 [TBL] [Abstract][Full Text] [Related]
15. Morphological profile and association of HER-2/neu with prognostic markers in breast carcinoma in Northern Pakistan. Sharif MA; Mamoon N; Mushtaq S; Khadim MT J Coll Physicians Surg Pak; 2009 Feb; 19(2):99-103. PubMed ID: 19208313 [TBL] [Abstract][Full Text] [Related]
16. Steroid hormone receptor association with prognostic markers in breast carcinoma in Northern Pakistan. Sharif MA; Mamoon N; Mushtaq S; Khadim MT; Jamal S J Coll Physicians Surg Pak; 2010 Mar; 20(3):181-5. PubMed ID: 20392381 [TBL] [Abstract][Full Text] [Related]
17. Determination of threshold values for determining the size of the fraction of steroid hormone receptor-positive tumor cells in paraffin-embedded breast carcinomas. Leers MP; Hoop JG; van Beers M; van Rodijnen N; Pannebakker M; Nap M Cytometry B Clin Cytom; 2005 Mar; 64(1):43-52. PubMed ID: 15668953 [TBL] [Abstract][Full Text] [Related]
18. Evaluation of oestrogen and progesterone receptor status in HER-2 positive breast carcinomas and correlation with outcome. Francis G; Beadle G; Thomas S; Mengersen K; Stein S Pathology; 2006 Oct; 38(5):391-8. PubMed ID: 17008275 [TBL] [Abstract][Full Text] [Related]
19. [Expression of estrogen and progesterone receptors and oncoprotein HER-2 as a marker for clinical course and outcome in endometrioid adenocarcinoma of the uterine body (immunohistologic study)]. Samsonova EA; Maksimova NA; Urmancheeva AF; Pozharisskiĭ KM Vopr Onkol; 2004; 50(2):196-201. PubMed ID: 15176223 [TBL] [Abstract][Full Text] [Related]
20. Breast cancer subtype approximated by estrogen receptor, progesterone receptor, and HER-2 is associated with local and distant recurrence after breast-conserving therapy. Nguyen PL; Taghian AG; Katz MS; Niemierko A; Abi Raad RF; Boon WL; Bellon JR; Wong JS; Smith BL; Harris JR J Clin Oncol; 2008 May; 26(14):2373-8. PubMed ID: 18413639 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]